Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention

Caocci, Giovanni; Mulas, Olga; Bonifacio, Massimiliano; Abruzzese, Elisabetta; Galimberti, Sara; Orlandi, Ester Maria; Iurlo, Alessandra; Annunziata, Mario; Luciano, Luigiana; Castagnetti, Fausto; Gozzini, Antonella; Stagno, Fabio; Binotto, Gianni; Pregno, Patrizia; Albano, Francesco; Martino, Bruno; Fozza, Claudio; Scaffidi, Luigi; Trawinska, Malgorzata Monika; Baratè, Claudia; Elena, Chiara; Cattaneo, Daniele; Scalzulli, Emilia; La Nasa, Giorgio; Foà, Robin; Breccia, Massimo

doi:10.1016/j.ijcard.2019.04.051

Risk of death is particularly high in patients with a previous history of arterial occlusive events (AOEs) and the probability for a recurrent event is around 20%. Little is known about recurrent AOE and the role of secondary prevention in patients with Chronic Myeloid Leukemia (CML) with previous AOE, treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs), nilotinib, dasatinib, bosutinib and ponatinib.

Titolo:	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention
Autori:	Caocci, Giovanni Mulas, Olga BONIFACIO, Massimiliano Abruzzese, Elisabetta Galimberti, Sara Orlandi, Ester Maria Iurlo, Alessandra Annunziata, Mario Luciano, Luigiana Castagnetti, Fausto Gozzini, Antonella Stagno, Fabio Binotto, Gianni Pregno, Patrizia Albano, Francesco Martino, Bruno Fozza, Claudio SCAFFIDI, Luigi Trawinska, Malgorzata Monika Baratè, Claudia Elena, Chiara Cattaneo, Daniele Scalzulli, Emilia La Nasa, Giorgio Foà, Robin Breccia, Massimo mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2019
Rivista:	INTERNATIONAL JOURNAL OF CARDIOLOGY
Abstract:	Risk of death is particularly high in patients with a previous history of arterial occlusive events (AOEs) and the probability for a recurrent event is around 20%. Little is known about recurrent AOE and the role of secondary prevention in patients with Chronic Myeloid Leukemia (CML) with previous AOE, treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs), nilotinib, dasatinib, bosutinib and ponatinib.
Handle:	http://hdl.handle.net/11562/1015813
Appare nelle tipologie:	01.01 Articolo in Rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11562/1015813

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CATALOGO DEI PRODOTTI DELLA RICERCA

File in questo prodotto: